Johnston C C, Khairi M R, Meunier P J
Arthritis Rheum. 1980 Oct;23(10):1172-6. doi: 10.1002/art.1780231015.
Etidronate used in recommended doses (usually 5 mg/kg/day for 6 months) produces symptomatic improvement in approximately 60% of patients. The serum alkaline phosphatase and urinary hydroxyproline are reduced to about 50% of initial values. A sustained remission occurs in many patients and retreatment is usually effective upon relapse. The abnormally elevated osteoclast count and resorption surfaces are reduced, and at the low dose there is no accumulation of osteoid. The medication is generally well tolerated and at the recommended dosage there is no evidence of increased fracture rate.
依替膦酸以推荐剂量使用（通常为5毫克/千克/天，持续6个月）可使约60%的患者症状得到改善。血清碱性磷酸酶和尿羟脯氨酸降至初始值的约50%。许多患者会出现持续缓解，复发时再次治疗通常有效。异常升高的破骨细胞数量和吸收表面减少，低剂量时无类骨质积聚。该药物一般耐受性良好，在推荐剂量下没有证据表明骨折率增加。
